Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Genetics Inks Distribution Deal with Fisher HealthCare for ForeCYTE

NEW YORK (GenomeWeb News) – Atossa Genetics today announced a distribution deal with Thermo Fisher Scientific's Fisher HealthCare for Atossa's ForeCYTE breast cancer test.

Fisher Healthcare will distribute the ForeCYTE Breast Health device, consisting of Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT, pump and ForeCYTE patient collection kits. ForeCYTE is a risk stratification test for breast cancer.

Financial and other terms of the deal were not disclosed.

Earlier this week, Atossa announced an agreement with preferred provider organization HealthSmart. Last month, the Seattle-based company signed a deal with Millennium Healthcare for distribution of ForeCYTE in the New York metro area and northern New Jersey.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.